• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chronic Plaque Psoriasis - Pipeline Review, H2 2012 Product Image

Chronic Plaque Psoriasis - Pipeline Review, H2 2012

  • ID: 2298950
  • October 2012
  • 86 pages
  • Global Markets Direct

Chronic Plaque Psoriasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. Chronic Plaque Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Plaque Psoriasis.
- A review of the Chronic Plaque Psoriasis products under development READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Chronic Plaque Psoriasis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chronic Plaque Psoriasis 8
Chronic Plaque Psoriasis Therapeutics under Development by Companies 10
Chronic Plaque Psoriasis Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Chronic Plaque Psoriasis Therapeutics – Products under Development by Companies 15
Chronic Plaque Psoriasis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Chronic Plaque Psoriasis Therapeutics Development 17
Alcon, Inc. 17
Abbott Laboratories 18
Eli Lilly and Company 19
Biotest AG 20
Merck & Co., Inc. 21
AbGenomics International, Inc. 22
ApoPharma 23
Astellas Pharma Inc. 24
Eisai Co., Ltd. 25
Pfizer Inc. 26
Incyte Corporation 27
Can-Fite BioPharma Ltd. 28
Lupin Limited 29
Chronic Plaque Psoriasis – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ASP-015-K - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ixekizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tofacitinib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
baricitinib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
secukinumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
tregalizumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AbGn-168H - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
E-6201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
briakinumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CF 101 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LL-4218 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
halobetasol propionate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
apremilast - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MK-3222 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Apo-805-K1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
INCB039110 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Chronic Plaque Psoriasis Therapeutics – Drug Profile Updates 61
Chronic Plaque Psoriasis Therapeutics – Discontinued Products 74
Chronic Plaque Psoriasis Therapeutics - Dormant Products 75
Chronic Plaque Psoriasis – Product Development Milestones 76
Featured News & Press Releases 76
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 76
Jan 09, 2012: Biocon Announces Positive Efficacy Data With Itolizumab In Pivotal Psoriasis Study 77
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 78
May 25, 2011: Centocor's New Stelara Data Shows Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis 79
Apr 15, 2011: Merck and Johnson & Johnson Reach Agreement on Distribution Rights for Remicade and Simponi 80
Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA 81
Sep 14, 2010: Biotie's Phase I Trial With BTT-1023 Demonstrates Safety Profile 81
Sep 02, 2010: Avesthagen Obtains Indian Patent For AVENT 82
Jun 01, 2010: Avesthagen Moves Towards Clinicals Of Biosimilar AVENT 83
Jan 20, 2010: Fully Human Monoclonal Anti-TNF-alpha Antibody Humira Receives Approval as Japan's First Biological Agent for Psoriasis 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Number of Products Under Development for Chronic Plaque Psoriasis, H2 2012 8
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Alcon, Inc., H2 2012 17
Abbott Laboratories, H2 2012 18
Eli Lilly and Company, H2 2012 19
Biotest AG, H2 2012 20
Merck & Co., Inc., H2 2012 21
AbGenomics International, Inc., H2 2012 22
ApoPharma, H2 2012 23
Astellas Pharma Inc., H2 2012 24
Eisai Co., Ltd., H2 2012 25
Pfizer Inc., H2 2012 26
Incyte Corporation, H2 2012 27
Can-Fite BioPharma Ltd., H2 2012 28
Lupin Limited, H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Chronic Plaque Psoriasis Therapeutics – Drug Profile Updates 61
Chronic Plaque Psoriasis Therapeutics – Discontinued Products 74
Chronic Plaque Psoriasis Therapeutics – Dormant Products 75

List of Figures
Number of Products under Development for Chronic Plaque Psoriasis, H2 2012 8
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos